Back to Market Feed

Product Information

COBENFY 100 MG-20 MG CAPSULE is a brand product labeled by E.R. Squibb & Sons, L.L.C., priced at $30.1500 per EA under NDC 00003110060. Its NADAC has been published 75 times since Mar 19, 2025.

FDA first approved this application on Sep 26, 2024.

COBENFY 100 MG-20 MG CAPSULE

xanomeline and trospium chloride
$30.1500per EA

Strength

20; 100 mg/1; mg/1

NDC

00003110060

Classification

Brand

Dosage Form

CAPSULE, COATED PELLETS

Route

ORAL

Effective Date

8/19/2026

Approval Type

New Drug (NDA)

FDA Application

NDA216158

FDA Approved

9/26/2024

On Market Since

9/27/2024

Pharmacological Classes

Cholinergic Muscarinic Agonist
Cholinergic Muscarinic Agonists
Cholinergic Muscarinic Antagonist
Cholinergic Muscarinic Antagonists
Cytochrome P450 3A4 Inhibitors
P-Glycoprotein Inhibitors

Price Statistics

The NADAC for COBENFY 100 MG-20 MG CAPSULE has been published 75 times since Mar 19, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.

Current price$30.1500 per EA
All-time high$30.3016 (May 13, 2026)
All-time low$29.6495 (Sep 17, 2025)
52-week high$30.3016
52-week low$29.6495
Median price$29.7075
Average price$29.9178
Largest weekly change+2.0% (Jan 14, 2026)
Weeks tracked75
Tracking sinceMar 19, 2025

Price History

1W

-0.0%

1M

-0.0%

3M

+0.0%

6M

-0.5%

1Y

+1.7%

3Y

N/A

5Y

N/A

All

+1.4%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the xanomeline and trospium chloride market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

CUVPOSA 1 MG/5 ML SOLUTION
Brand
00259050116•Merz Pharmaceuticals, LLC
$1.0080
per ML
TIAZAC ER 180 MG CAPSULE
Brand
00187261330•Bausch Health US LLC
$1.5060
per EA
TIAZAC ER 180 MG CAPSULE
Brand
00187261390•Bausch Health US LLC
$1.5060
per EA
VESICARE LS 5 MG/5 ML SUSP
Brand
51248025099•Astellas Pharma US, Inc.
$1.6383
per ML
MYRBETRIQ ER 8 MG/ML SUSP
Brand
00469502099•Astellas Pharma US, Inc.
$2.2069
per ML
OXYTROL FOR WOMEN 3.9 MG/24HR
Brand
00023963704•Allergan, Inc.
$2.7497
per EA
OXYTROL FOR WOMEN 3.9 MG/24HR
Brand
00023963708•Allergan, Inc.
$2.7497
per EA
ZONISADE 100 MG/5 ML ORAL SUSP
Brand
52652800101•Azurity Pharmaceuticals Inc.
$2.7505
per ML
TIAZAC ER 360 MG CAPSULE
Brand
00187261630•Bausch Health US LLC
$2.7628
per EA
TIAZAC ER 360 MG CAPSULE
Brand
00187261690•Bausch Health US LLC
$2.7628
per EA

Frequently asked questions

What is the NADAC price of COBENFY 100 MG-20 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for COBENFY 100 MG-20 MG CAPSULE, manufactured by E.R. Squibb & Sons, L.L.C., is $30.1500 per EA (NDC 00003110060), effective Aug 19, 2026.

How has the price of COBENFY 100 MG-20 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for COBENFY 100 MG-20 MG CAPSULE has held within roughly two percent of its current level. It has been tracked across 75 weekly CMS publications since Mar 19, 2025.

What are the highest and lowest recorded NADAC prices for COBENFY 100 MG-20 MG CAPSULE?

Since Mar 19, 2025, the NADAC for COBENFY 100 MG-20 MG CAPSULE has ranged from a low of $29.6495 (Sep 17, 2025) to a high of $30.3016 (May 13, 2026), with a median of $29.7075 per EA.

Are there cheaper alternatives to COBENFY 100 MG-20 MG CAPSULE?

No other NADAC-published product currently shares the active ingredient and strength of COBENFY 100 MG-20 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures COBENFY 100 MG-20 MG CAPSULE?

COBENFY 100 MG-20 MG CAPSULE (NDC 00003110060) is labeled by E.R. Squibb & Sons, L.L.C., and CMS classifies it as a brand product.